Prosecution Insights
Last updated: July 17, 2026
Application No. 17/596,491

TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF

Final Rejection §102§112
Filed
Dec 10, 2021
Priority
Jun 12, 2019 — provisional 62/860,328 +1 more
Examiner
MARTIN, KEVIN STEPHEN
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Governors of the University of Alberta
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
110 granted / 146 resolved
+15.3% vs TC avg
Strong +24% interview lift
Without
With
+24.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
43 currently pending
Career history
179
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
34.8%
-5.2% vs TC avg
§102
14.5%
-25.5% vs TC avg
§112
36.8%
-3.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 146 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims and Response to Amendments The amendments filed April 29, 2026 have been acknowledged and entered. Claims 1-15 are pending. Election/Restriction The present examination is based on Applicant’s election without traverse of Group I (claims 1-7) and species corresponding to A4 in the reply filed on September 19, 2025. Applicant has overcome the art rejections previously set forth. The search has been expanded to a compound of formula PNG media_image1.png 391 501 media_image1.png Greyscale . And new art was found. Withdrawn Rejections Applicant is notified that any outstanding rejection or objection that is not expressly maintained in this Office Action has been withdrawn or rendered moot in view of Applicant’s amendments and/or remarks. Rejections Necessitated by Applicant Amendment Claim Rejections - 35 USC § 112a The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 1-7 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. If new matter is added to the claims, the examiner should reject the claims under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph - written description requirement. In re Rasmussen, 650 F.2d 1212, 211 USPQ 323 (CCPA 1981). See MPEP 2163.06. Claim 1 has been amended to recite a genus corresponding to a compound of formula PNG media_image1.png 391 501 media_image1.png Greyscale ; however, this genus is not described in the specification. Moreover, this new genus includes new arrangements/definitions of variables which are not supported in the specification. For instance, the specification as filed teaches R3 is an optional substituent on R2 (see formula (I) at paragraph [0050] and paragraph [0054]); however, the present amendment newly defines R2 as a variable on the above phenyl ring. Similarly, the specification teaches R2 is a substituent on the piperazinyl ring of formula (I) (see paragraph [0035]); however, the present amendment newly defines R2 as a variable on the above phenyl ring. Additionally, there is no support in the specification for generic structures PNG media_image2.png 141 234 media_image2.png Greyscale and PNG media_image3.png 137 240 media_image3.png Greyscale . The specification does not even appear to recite R6, R7 and R8 or R9 and R10. These amendments are new matter. It is suggested the claims be amended to delete the new matter. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Stavrovskaya, V. I. (Zhurnal Obshchei Khimii (1955), 25, Abstract) (hereinafter “Stavrovskaya”). Stavrovskaya teaches a compound of the claims (see attached Abstract; pictured below) wherein X is CH; R1 is Me; R2 PNG media_image4.png 145 244 media_image4.png Greyscale ; R3 PNG media_image5.png 134 246 media_image5.png Greyscale ; and each of R5, R6, R7 and R8 is Et. PNG media_image6.png 256 323 media_image6.png Greyscale Conclusion No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to KEVIN MARTIN whose telephone number is (571)270-0917. The examiner can normally be reached Monday - Friday 8 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on (571) 272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. June 1, 2026 /K.S.M./Examiner, Art Unit 1624 /BRUCK KIFLE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Dec 10, 2021
Application Filed
Oct 29, 2025
Non-Final Rejection mailed — §102, §112
Apr 29, 2026
Response Filed
Apr 29, 2026
Response after Non-Final Action
Jun 04, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678431
PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DEMENTIA AND CEREBROVASCULAR DISORDERS
5y 0m to grant Granted Jul 14, 2026
Patent 12679833
N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS
3y 7m to grant Granted Jul 14, 2026
Patent 12673106
MODULATORS OF NUCLEAR RECEPTOR SUBFAMILY 4 GROUP A MEMBER 1 (NR4A1) AND USES THEREOF
3y 4m to grant Granted Jul 07, 2026
Patent 12667552
DIETARY BUTYRATE
5y 0m to grant Granted Jun 30, 2026
Patent 12662465
EGFR INHIBITORS
3y 10m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
99%
With Interview (+24.5%)
3y 5m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 146 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month